30.10.2022 Fresenius SE & Co. KGaA  DE0005785604

EQS-Adhoc: Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised


 

EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Change in Forecast
Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised

30-Oct-2022 / 17:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Fresenius SE & Co. KGaA: Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised
Since Fresenius Medical Care continues to operate in a challenging environment, the impacts of the Company’s focused efforts to improve North American Health Care Services operations are delayed against previous assumptions. Therefore, Fresenius Medical Care now assumes lower contributions in the financial year 2022.

Consequently, Fresenius Medical Care now expects net income (attributable to shareholders of Fresenius Medical Care AG & Co. KGaA) for the financial year 2022 to decline in the high teens to mid-twenties percentage range. The Company continues to anticipate revenue to grow at a low-single digit percentage range in the financial year 2022. These targets are in constant currency and exclude special items.

All other business segments of the Fresenius Group, in particular Vamed, are also affected by a challenging overall economic environment. Thus, there are increased uncertainties, inflation-related cost increases, staff shortages, disruptions in supply chains, and increased energy costs. This has a direct impact on customer and patient behavior.

However, as a consequence of the development at Fresenius Medical Care, Fresenius Vamed, and in view of increasing indications of a persistent unfavorable development of these and other factors for the further course of the financial year, the Management Board has changed its risk assessment and consequently also adjusted the Group outlook for FY/22.

At constant currency, the Company now anticipates Group net income1,2 to decline around ten percent (previously: decline in a low-to-mid single-digit percentage range). Group sales3 in constant currency continue to be expected to grow in a low-to-mid single-digit percentage range.

The acquisition of Ivenix and the acquisition of the majority stake in mAbxience as well as any further potential acquisitions remain excluded from guidance.

1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
2 FY/21 base: €1,867 million, before special items; 2022: before special items
3 FY/21 base: €37,520 million

For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures.


Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
The Management Board

Bad Homburg v.d.H., October 30, 2022


----------------------------------------
Contact:
Markus Georgi
Senior Vice President Investor Relations & Sustainability 
T: +49 (0) 6172 608-2485
[email protected]
----------------------------------------

End of Note
 

30-Oct-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: [email protected]
Internet: www.fresenius.com
ISIN: DE0005785604
WKN: 578560
Indices: DAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange
EQS News ID: 1475045

 
End of Announcement EQS News Service

1475045  30-Oct-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1475045&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 29.083,00 33.530,00 35.409,00 37.250,00 36.277,00 37.520,00 39.695,00
EBITDA1,2 5.500,00 6.267,00 6.032,00 7.083,00 7.132,00 6.854,00 0,00
EBITDA-Marge3 18,91 18,69 17,04 19,01 19,66 18,27 0,00
EBIT1,4 4.327,00 4.589,00 5.251,00 4.631,00 4.385,00 4.252,00 4.990,00
EBIT-Marge5 14,88 13,69 14,83 12,43 12,09 11,33 12,57
Jahresüberschuss1 2.676,00 1.816,00 1.871,00 1.915,00 2.823,00 1.867,00 2.035,00
Netto-Marge6 9,20 5,42 5,28 5,14 7,78 4,98 5,13
Cashflow1,7 3.574,00 3.937,00 3.742,00 4.263,00 6.549,00 5.078,00 5,58
Ergebnis je Aktie8 2,83 3,25 3,37 3,44 3,06 3,26 2,45
Dividende8 0,62 0,75 0,80 0,84 0,88 0,92 0,70
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Fresenius
WKN Kurs in € Einschätzung Börsenwert in Mio. €
578560 26,370 Kaufen 14.852,57
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
11,99 16,98 0,72 9,03
KBV KCV KUV EV/EBITDA
0,80 2,92 0,40 5,73
Dividende '22 in € Dividende '23e in € Div.-Rendite '22e
in %
Hauptversammlung
0,70 0,70 2,65 17.05.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
09.05.2023 02.08.2023 01.11.2022 24.03.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
0,86% -1,59% 0,46% -29,01%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Fresenius SE & Co. KGaA  ISIN: DE0005785604 können Sie bei EQS abrufen


Medtech , 578560 , FRE , XETR:FRE